By Juan Carlos Rodriguez

Law360, New York (January 09, 2012, 6:48 PM ET) -- Drugmaker Shire LLC on Monday hit rival Sandoz Inc. with a second patent suit in Colorado federal court over Sandoz’s proposal to manufacture a generic version of the attention deficit hyperactivity disorder drug Intuniv.

Shire filed the lawsuit after Sandoz, the generic-pharmaceuticals division of Novartis AG, amended its application to make the generic version to include 1-milligram, 2-milligram and 3-milligram dosages. Sandoz's original application was for a 4-milligram dose.

Dublin-based Shire claims Sandoz's generic version, in any dosage, would violate three Intuniv patents.

Shire says it...